Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04759261
Status:
UNKNOWN
Last Update Posted:
2021-02-18
First Post:
2021-02-09
Brief Title:
SMAD4 Methylation and Expression Levels in Non-melanocytic Skin Cancers SMAD4 Protein Positivity
Sponsor:
Trakya University
Organization:
Trakya University
Study Overview
Official Title:
SMAD4 Methylation and Expression Levels in Non-melanocytic Skin Cancers SMAD4 Protein Positivity
Status:
UNKNOWN
Status Verified Date:
2021-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Non-melanocytic skin cancers are the most common type of cancer worldwide In the development of this cancer type environmental factors such as UV and smoking are emphasized
Epigenetics are genetic conditions that develop due to environmental factors and can be inherited Epigenetic modifications such as DNA methylation play an integral role in carcinogenesis cancer progression and metastasis
The TGF- SMAD4 pathway plays a tumor suppressive role in cancer pathogenesis Epigenetic changes in this pathway also lead to a decrease in expression level leading to different types of cancer However there is no study showing the epigenetic relationship between non-melanocytic skin cancer and SMAD4 methylation
In this study we planned it was aimed to show the change in SMAD4 methylation and SMAD4 RNA expression level in cancerous tissue In addition it is planned to measure the SMAD4 protein positivity rate in non-melanocytic cancers as an immunohistochemical marker
In this context 60 patients who applied to Trakya University Dermatology and Venereal Diseases Outpatient Clinic and diagnosed with non-melanocytic skin cancer clinically and dermoscopically will be included in the study Tissue materials obtained from both cancerous and intact skin of the patients will be examined in Trakya University Medical Biophysics and Medicine Pathology laboratories through various steps
Our project is the first study to be conducted on this subject in terms of handling all non-melanocytic skin cancers using human tissue and having a large sample
In addition with the data to be obtained We think that better clarification of the role of SMAD4 in non-melanocytic cancers and the use of SMAD4 as both a prognostic factor and an immunohistochemical marker in future studies will prevent this study
Again we anticipate that different treatment modalities will be developed and different functional studies can be designed through this pathway
Epigenetics are genetic conditions that develop due to environmental factors and can be inherited Epigenetic modifications such as DNA methylation play an integral role in carcinogenesis cancer progression and metastasis
The TGF- SMAD4 pathway plays a tumor suppressive role in cancer pathogenesis Epigenetic changes in this pathway also lead to a decrease in expression level leading to different types of cancer However there is no study showing the epigenetic relationship between non-melanocytic skin cancer and SMAD4 methylation
In this study we planned it was aimed to show the change in SMAD4 methylation and SMAD4 RNA expression level in cancerous tissue In addition it is planned to measure the SMAD4 protein positivity rate in non-melanocytic cancers as an immunohistochemical marker
In this context 60 patients who applied to Trakya University Dermatology and Venereal Diseases Outpatient Clinic and diagnosed with non-melanocytic skin cancer clinically and dermoscopically will be included in the study Tissue materials obtained from both cancerous and intact skin of the patients will be examined in Trakya University Medical Biophysics and Medicine Pathology laboratories through various steps
Our project is the first study to be conducted on this subject in terms of handling all non-melanocytic skin cancers using human tissue and having a large sample
In addition with the data to be obtained We think that better clarification of the role of SMAD4 in non-melanocytic cancers and the use of SMAD4 as both a prognostic factor and an immunohistochemical marker in future studies will prevent this study
Again we anticipate that different treatment modalities will be developed and different functional studies can be designed through this pathway
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SMAD4 | OTHER | Trakya University | None |